NRx submits 70,000-patient ketamine data to US FDA
NRx Pharmaceuticals (Nasdaq: NRXP) will submit real-world evidence from over 70,000 patients treated with intravenous ketamine…
uniQure Provides FDA Update on AMT-130; BLA Timing Unclear
uniQure (NASDAQ: QURE) on Nov. 3, 2025 announced FDA feedback…